Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
出版年份 2017 全文链接
标题
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 8, Pages e1338997
出版商
Informa UK Limited
发表日期
2017-06-28
DOI
10.1080/2162402x.2017.1338997
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
- (2017) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients
- (2017) Mina Nikanjam et al. ONCOLOGIST
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
- (2016) Mina Nikanjam et al. INTERNATIONAL JOURNAL OF CANCER
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
- (2016) Benjamin Herzberg et al. ONCOLOGIST
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
- (2016) Sariah Liu et al. Oncotarget
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
- (2016) Sadakatsu Ikeda et al. npj Genomic Medicine
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials
- (2012) S. Gupta et al. JNCI-Journal of the National Cancer Institute
- CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
- (2012) L. Wu et al. MOLECULAR CANCER THERAPEUTICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials
- (2012) Mitesh J. Borad et al. Journal of Cancer
- CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
- (2011) Y. Zhu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Dose-escalation models for combination phase I trials in oncology
- (2010) Paul Hamberg et al. EUROPEAN JOURNAL OF CANCER
- Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
- (2010) Christophe Le Tourneau et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Drug Combination Trial Design: Walking the Tightrope
- (2009) Paul Hamberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
- (2008) C.-W. Tseng et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search